- Home
- SLXN vs EONR Comparison
SLXN vs EONR Comparison
Compare SLXN & EONR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- EONR
- Stock Information
- Founded
- SLXN 2008
- EONR 2017
- Country
- SLXN Israel
- EONR United States
- Employees
- SLXN N/A
- EONR N/A
- Industry
- SLXN
- EONR
- Sector
- SLXN
- EONR
- Exchange
- SLXN NYSE
- EONR NYSE
- Market Cap
- SLXN 7.3M
- EONR 6.8M
- IPO Year
- SLXN N/A
- EONR N/A
- Fundamental
- Price
- SLXN $0.80
- EONR $0.39
- Analyst Decision
- SLXN Strong Buy
- EONR Strong Buy
- Analyst Count
- SLXN 1
- EONR 1
- Target Price
- SLXN $5.00
- EONR $2.00
- AVG Volume (30 Days)
- SLXN 141.1K
- EONR 15.1M
- Earning Date
- SLXN 08-21-2025
- EONR 08-15-2025
- Dividend Yield
- SLXN N/A
- EONR N/A
- EPS Growth
- SLXN N/A
- EONR N/A
- EPS
- SLXN N/A
- EONR N/A
- Revenue
- SLXN N/A
- EONR $19,638,616.00
- Revenue This Year
- SLXN N/A
- EONR $46.94
- Revenue Next Year
- SLXN N/A
- EONR $64.38
- P/E Ratio
- SLXN N/A
- EONR N/A
- Revenue Growth
- SLXN N/A
- EONR N/A
- 52 Week Low
- SLXN $0.58
- EONR $0.33
- 52 Week High
- SLXN $41.85
- EONR $2.92
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- EONR N/A
- Support Level
- SLXN N/A
- EONR N/A
- Resistance Level
- SLXN N/A
- EONR N/A
- Average True Range (ATR)
- SLXN 0.00
- EONR 0.00
- MACD
- SLXN 0.00
- EONR 0.00
- Stochastic Oscillator
- SLXN 0.00
- EONR 0.00
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
About EONR EON RESOURCES INC
EON Resources Inc is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. Its current focus is as an upstream energy company producing oil and gas properties in the Permian Basin.